Lv11
10 积分 2025-06-24 加入
FDA approves TROP2-targeted antibody–drug conjugate for breast cancer
57分钟前
已完结
Improved biodistribution and antitumor effects of a Nectin4 and Trop2 bispecific fatty acid-modified nanobody conjugate
1小时前
已完结
A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer
1个月前
已完结
Ozoralizumab: First Approval
3个月前
已完结
Research trends in the use of nanobodies for cancer therapy
3个月前
已完结
Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
4个月前
已完结
Structure-guided design and engineering of a biparatopic antibody targeting CCR2 in triple negative breast cancer
4个月前
已完结
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
4个月前
已完结
A mechanism for hypoxia-induced inflammatory cell death in cancer
4个月前
已完结
Artificial intelligence in cancer immunotherapy: Applications in neoantigen recognition, antibody design and immunotherapy response prediction
4个月前
已完结
皖公网安备34019202002308
